Repository of Research and Investigative Information

Repository of Research and Investigative Information

Baqiyatallah University of Medical Sciences

Changes in Body Mass Index and Lipid Profile in Psoriatic Patients After Treatment With Standard Protocol of Infliximab

(2016) Changes in Body Mass Index and Lipid Profile in Psoriatic Patients After Treatment With Standard Protocol of Infliximab. Acta Med Iran. pp. 570-575. ISSN 0044-6025

[img] Text
Changes in Body Mass Index and Lipid Profile in Psoriatic Patients After Treatment With Standard Protocol of Infliximab..pdf

Download (192kB)

Official URL: http://www.ncbi.nlm.nih.gov/pubmed/27832688

Abstract

Psoriasis is a chronic and inflammatory dermatologic disease. Psoriasis may predispose to cardiovascular disease and diabetes. However, the role of tumor necrosis factor (TNF) inhibitor in mediating this risk is controversial. Regarding frequent use of infliximab in psoriasis, and the hypothesis that anti TNF-alpha treatment may increase Body Mass Index (BMI) and alter lipid profile in these patients, the aim of this study was to assess changes in BMI and Lipid Profile and level of leptin in Psoriatic Patients under Treatment of Standard Protocol of Infliximab in a 24 week period. This study was accomplished as a before-after study. Twenty-seven psoriatic patients were included, and standard infliximab therapy was applied. All patients underwent 3 times of blood collection and in each session; LDL, HDL, Total Cholesterol, Triglycerides, Leptin, and PASI score were measured at the start of the study and at the 12th and 24th week of follow-up. Twenty-five patients consisted of 18 (72) male and 7 (28) female subjects were evaluated. The mean age of the patients was 36.91+/-13.31 years. PASI score demonstrated significant decrease after 24 weeks; however, BMI and HDL and leptin showed a significant increase during treatment. Significant negative correlation was seen between Leptin and PASI score changes (r=0.331, P=0.042). HDL and BMI had the most correlations with leptin (positive correlation) and PASI score (negative correlation). Results demonstrated a dramatic decrease in PASI, increase in BMI and HDL and increased in leptin; somewhat correlated to each other. These results suggest that patients taking infliximab should take more care of their weight and lipid profile, while on treatment.

Item Type: Article
Keywords: Adult Body Mass Index Body Weight Female Humans Infliximab/adverse effects/*therapeutic use Lipids/*blood Male Middle Aged Psoriasis/blood/*drug therapy Severity of Illness Index Tumor Necrosis Factor-alpha/antagonists & inhibitors Young Adult Infliximab Lipid profile Psoriasis
Divisions:
Page Range: pp. 570-575
Journal or Publication Title: Acta Med Iran
Journal Index: Pubmed
Volume: 54
Number: 9
ISSN: 0044-6025
Depositing User: مهندس مهدی شریفی
URI: http://eprints.bmsu.ac.ir/id/eprint/1608

Actions (login required)

View Item View Item